Today, a Director at Melinta Therapeutics Inc (NASDAQ: MLNT), David Gill, bought shares of MLNT for $30.45K.
Following this transaction David Gill’s holding in the company was increased by 500% to a total of $37.8K. This is Gill’s first transaction since reporting a Buy transaction on HSGX back in August 2017
See today’s analyst top recommended stocks >>
Based on Melinta Therapeutics Inc’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $14.84 million and GAAP net loss of $29.43 million. In comparison, last year the company earned revenue of $4.87 million and had a GAAP net loss of $22.89 million. Currently, Melinta Therapeutics Inc has an average volume of 522.8K.
14 different firms, including Cantor Fitzgerald and Cowen & Co., currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Melinta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the discover, development and commercialization of antibiotics. Its product, Baxbela, is used in the treatment of acute bacterial skin and skin structure infections.
